Dataset | Source | Tissue | Cancer type level1 | Cancer type level2 | Drug type | Regimen | Timepoint | Cell type | avg_log2FC | p_val_adj |
GSE140440 | DU145 and PCÂ cell lines | Cell line | Prostate cancer | Prostate cancer | Chemotherapy | docetaxel | NA | Malignant cells | 0.979829 | 2.05e-05 |
GSE163836 | FCIBC02 cell line | Cell line | Breast cancer | Inflammatory breast cancer | Chemotherapy | paclitaxel | NA | Malignant cells | -0.478671 | 0.00e+00 |
GSE197268_Axi-cel | patients | Peripheral blood mononuclear cells | Acute lymphoblastic leukemia | Large B-cell acute lymphoblastic leukemia (B-ALL) | Immunotherapy | axi-cel (CAR-T) | post | CD8+ T cells | -0.256328 | 0.00e+00 |
PMID34715028 | patients | Tumor tissue | Kidney cancer | Clear cell renal cell carcinoma (ccRCC) | Immunotherapy | nivolumab | post | CD4+ T cells | -0.37953 | 6.43e-32 |
PMID34715028 | patients | Tumor tissue | Kidney cancer | Clear cell renal cell carcinoma (ccRCC) | Immunotherapy | nivolumab | post | CD8+ T cells | -0.309122 | 0.00e+00 |
GSE207422_Sin | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post | CD4+ T cells | 0.328765 | 5.94e-09 |
GSE207422_Sin | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post | CD8+ T cells | 0.288999 | 2.21e-10 |
GSE197268_Tisa-cel | patients | Peripheral blood mononuclear cells | Acute lymphoblastic leukemia | Large B-cell acute lymphoblastic leukemia (B-ALL) | Immunotherapy | tisa-cel (CAR-T) | post | CD4+ T cells | 0.267423 | 0.00e+00 |
GSE139386 | H3122 cell line | Cell line | Lung cancer | EML4-ALK fusion-positive non-small cell lung cancer (NSCLC) | Targeted therapy | ceritinib | NA | Malignant cells | 0.366203 | 0.00e+00 |
GSE199333 | patients | Bone marrow aspirate | Acute myeloid leukemia | Primary FLT3-ITD-mutated acute myeloid leukemia (AML) | Targeted therapy | gilteritinib | post | CD4+ T cells | -0.499651 | 0.00e+00 |
GSE108397 | 451Lu cell line | Cell line | Melanoma | Melanoma | Targeted therapy | PLX-4720 | NA | Malignant cells | -0.713217 | 0.00e+00 |
GSE175716 | PDX | Tumor tissue | Liver cancer | Advanced hepatocellular carcinoma | Targeted therapy | sorafenib | NA | Malignant cells | 0.288873 | 1.12e-04 |
GSE164897_VemCob | A375 cell line | Cell line | Melanoma | BRAFV600E-mutant melanoma | Targeted therapy | vemurafenib + combimetinib | NA | Malignant cells | -0.282315 | 0.00e+00 |
Gene symbol | motif | TF_highConf |
RHBDD2 | taipale_tf_pairs__ETS2_RCCGGAAGTG_HT | ETS2 (directAnnotation). |
RHBDD2 | jaspar__MA1483.2 | ELF2 (directAnnotation). |
RHBDD2 | taipale_tf_pairs__ATF4_TEF_RNMTGATGCAATN_CAP | ATF4; TEF (directAnnotation). |
RHBDD2 | taipale_tf_pairs__ATF4_CEBPD_NGATGATGCAATNN_CAP | ATF4; CEBPD (directAnnotation). |
RHBDD2 | transfac_pro__M05788 | ZNF569 (inferredBy_Orthology). |
RHBDD2 | taipale_tf_pairs__ATF4_CEBPB_NNATGAYGCAAYN_CAP | ATF4; CEBPB (directAnnotation). |
RHBDD2 | metacluster_52.11 | ZNF184 (directAnnotation). |
RHBDD2 | taipale_tf_pairs__GCM1_ELK1_RTGCGGGCGGAAGTN_CAP_2 | ELK1; GCM1 (directAnnotation). |
RHBDD2 | metacluster_191.3 | EHF; ELF1; ELF1; ELF1; ELF4; ELK1; ELK3; ELK3; ELK4; ELK4; ERF; ETS1; ETS2; ETV3; ETV4; ETV5; FEV; FEV; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; SPDEF; ZNF200 (directAnnotation). ELK1; ELK1; ELK3; ELK3; ELK4; ELK4; ETV1; ETV1; ETV4; ETV4; ETV4; ETV5; GABPA; GABPA (inferredBy_Orthology). |
RHBDD2 | metacluster_191.2 | ELK4; NR2C2; NR2C2; NR2C2; NR2C2 (directAnnotation). GABPA (inferredBy_Orthology). |
RHBDD2 | taipale_tf_pairs__ELF2_NATGCGGAAGTR_HT | ELF2 (directAnnotation). |
RHBDD2 | taipale_tf_pairs__ELK1_HOXA1_RCCGGAAGTAATTA_HT | ELK1; HOXA1 (directAnnotation). |
RHBDD2 | cisbp__M08198 | ELF1 (directAnnotation). |
RHBDD2 | taipale_tf_pairs__HOXD12_ELK3_NTTTAYNNCCGGAARNN_CAP_repr | ELK3; HOXD12 (directAnnotation). |
RHBDD2 | taipale_tf_pairs__ELK1_FOXI1_WGTTKMCGGAWRTN_CAP | ELK1; FOXI1 (directAnnotation). |
RHBDD2 | homer__TAATCCCN_Pitx1 | PITX1 (inferredBy_Orthology). |
RHBDD2 | tfdimers__MD00084 | ARID3A; NKX2-4 (directAnnotation). |
RHBDD2 | metacluster_92.4 | ZNF33B (directAnnotation). |
RHBDD2 | cisbp__M04019 | ATF6 (directAnnotation). |
RHBDD2 | jaspar__MA0684.2 | RUNX3 (directAnnotation). |
RHBDD2 | taipale_tf_pairs__GCM1_FOXI1_RTMAACATRNGGGN_CAP_repr | FOXI1; GCM1 (directAnnotation). |
RHBDD2 | tfdimers__MD00026 | IRF1; MYB (directAnnotation). |
RHBDD2 | transfac_pro__M06856 | ZNF611 (directAnnotation). |
RHBDD2 | transfac_pro__M05931 | ZNF556 (directAnnotation). |
RHBDD2 | transfac_pro__M05556 | ZNF784 (directAnnotation). |
RHBDD2 | transfac_pro__M06577 | ZNF594 (directAnnotation). |
RHBDD2 | jaspar__MA1583.1 | ZFP57 (directAnnotation). |
RHBDD2 | transfac_pro__M07448 | ZBED1 (directAnnotation). |
RHBDD2 | metacluster_117.2 | GATA3; GATA3; GATA3; GATA5; GATA5; GATA5; GATA5; GATA6; GATA6 (directAnnotation). |
RHBDD2 | taipale_cyt_meth__FOXO3_NTCCCCACACN_eDBD | FOXO3 (directAnnotation). |
RHBDD2 | taipale_cyt_meth__JUND_NRTGACGCATN_eDBD_repr | JUND (directAnnotation). |
RHBDD2 | jaspar__MA1125.1 | ZNF384 (directAnnotation). |
1 | "Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618." |
2 | "Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335." |